Regeneron Pharmaceuticals delivered a robust third-quarter performance, significantly surpassing Wall Street expectations, primarily fueled by the exceptional demand for its eczema treatment, Dupixent, and cancer drug Libtayo. This strong showing comes as the company prepares to resubmit its application for the pre-filled syringe version of higher-dose Eylea (Eylea HD), following a recent rejection from the U.S. Food and Drug Administration (FDA). Investors are keenly watching how Regeneron balances the sustained growth of its key assets against the ongoing regulatory challenges for its crucial eye drug pipeline.
On Tuesday, October 28, 2025, Regeneron Pharmaceuticals announced third-quarter results that sent its shares climbing by 8%. The pharmaceutical giant reported total revenue of $3.75 billion, comfortably exceeding analysts’ average estimate of $3.59 billion, according to data compiled by LSEG. The adjusted quarterly profit per share stood at $11.83, significantly higher than the anticipated $9.59. This robust financial performance underscores the company’s ability to execute effectively in a competitive market, driven largely by its diversified portfolio of high-demand treatments, as reported by Reuters.
For investors, Regeneron’s Q3 earnings offer a clearer picture of its underlying strength and resilience. While the headline news focused on an overall beat, a closer look at the individual drug performances reveals the true drivers of growth and potential long-term value.
Q3 Performance Highlights: Dupixent and Libtayo Lead the Charge
The stellar performance in the third quarter was primarily attributed to two blockbuster drugs:
- Dupixent: The anti-inflammatory drug, developed jointly with French drugmaker Sanofi, saw sales surge by 27% to $4.86 billion. This figure comfortably surpassed the estimate of $4.54 billion, highlighting its continued market dominance in treating conditions like eczema, asthma, and chronic rhinosinusitis with nasal polyps.
- Libtayo: Regeneron’s skin cancer treatment also contributed significantly, bringing in sales of $365 million, well above the $343.75 million estimated.
The consistent outperformance of these therapies is a critical indicator for long-term investors, demonstrating strong market penetration and demand, which helped cushion the impact of regulatory setbacks elsewhere in the portfolio, as further detailed by Bloomberg.
Eylea HD: Navigating Regulatory Hurdles
Despite the strong earnings, Regeneron faces ongoing challenges with its eye drug, Eylea, particularly the high-dose version, Eylea HD. The company announced plans to resubmit the marketing application for the pre-filled syringe version of Eylea HD after the FDA declined its approval on Monday. This setback is not isolated, as the company has been grappling with multiple regulatory delays for three pending Eylea applications due to issues at Catalent’s Bloomington filling facility.
The impact of manufacturing and supply chain complexities on pharmaceutical approvals is a well-known risk factor for investors. Regeneron CEO Leonard Schleifer openly addressed these issues, stating, “We recognize that it would be more ideal if we could have our own filling. We would have expected to have that by now, but we got delayed dramatically during COVID.” This transparency, while acknowledging past challenges, also signals a strategic shift towards greater self-sufficiency in manufacturing, a move that could de-risk future product launches.
Looking ahead, Regeneron anticipates submitting the new filler application by January 2026, with potential FDA approval by mid-2026. This timeline offers a crucial pathway for Eylea HD, which is designed to allow longer intervals between injections, a significant convenience for patients and a competitive advantage in the ophthalmology market.
Strategic Outlook and Investment Implications
The Q3 update provides a mixed but ultimately positive outlook for Regeneron. The continued strength of Dupixent and Libtayo demonstrates a robust core business capable of delivering growth even when other pipeline assets face delays. Cantor analyst Carter Gould noted that “the third-quarter update offered more detailed and potentially sooner de-risking of the new filler for Eylea HD than most investors anticipated,” suggesting a positive sentiment from the analyst community regarding the clarity of Regeneron’s path forward for Eylea HD.
Investor Takeaways: Balancing Risk and Reward
- Diversified Growth Engine: Dupixent’s impressive growth validates Regeneron’s strategy of developing broad-spectrum, high-impact therapies, reducing over-reliance on a single drug.
- Eylea’s Long-Term Potential: While Eylea HD faces hurdles, its benefits (longer injection intervals) are compelling. A successful resubmission and approval would strengthen its competitive position against rivals like Roche’s Vabysmo.
- Manufacturing Control: The CEO’s comments about owning filling capabilities highlight a move towards vertical integration, which, if successful, could reduce future regulatory and supply chain risks associated with third-party manufacturers like Catalent. This long-term strategic investment in infrastructure could be a significant value driver.
- Regulatory Patience: Investors should factor in the inherent volatility and timelines associated with pharmaceutical regulatory approvals. The mid-2026 approval target for the new filler suggests a measured approach, but any further delays would require careful reassessment.
For the dedicated investor in the pharmaceutical sector, Regeneron’s Q3 earnings present a compelling case for continued vigilance. The company is effectively navigating a complex landscape, leveraging the power of its established blockbusters while actively working to resolve regulatory challenges for its next generation of treatments. The focus on resolving manufacturing issues and the commitment to Eylea HD signal a strategic vision aimed at sustained long-term growth and market leadership.
